Ingressive Capital

Ingressive Capital is a Lagos-based early-stage venture firm that targets indigenous African talent across Sub-Saharan Africa, writing Pre-Seed and Seed checks in the $250k to $1M range. The fund’s positioning is unapologetically pan-African with a Nigerian center of gravity, and its LP base reaches into prominent global investors and operators who back the thesis that African markets need locally led capital with global standards. Healthcare exposure is one of several sectors, with the relevant surfaces being telemedicine, pharmacy and supply chain software, B2B health SaaS for clinics and hospitals, AI applications layered onto local clinical and claims data, and consumer health platforms. The right founder is an African technical or commercial operator with deep market understanding, building a B2B or B2C platform with realistic unit economics in a context where payment friction, infrastructure gaps, and FX volatility shape every product decision. Founders pursuing biotech, MedTech with multi-year regulatory pathways, or care delivery requiring large balance sheets should look at later-stage African PE funds. Geographic advantage is concrete. Ingressive’s network across Lagos, Nairobi, Cairo, Accra, and Cape Town gives founders access to operators, regulators, and corporate buyers in a way that diaspora-only funds cannot replicate. The team is also fluent in the structural risks African startups face, from cedi and naira moves to regulator unpredictability, and structures terms accordingly. Best entry path is a warm intro from a portfolio founder or a known African co-investor such as Future Africa, Voltron, or Norrsken22; cold inbound is acknowledged but conversion is meaningfully lower. Lead the pitch with a clear African wedge, real revenue or strong demand-side signals, and a sober view on the cross-border expansion playbook, given that each African market is a separate sales motion with its own regulator and payer logic. AI healthcare founders should describe the data asset, training pipeline, and how patient consent and data residency are handled under emerging African data protection laws. Caveats: at this check size, Ingressive is rarely a sole lead, so founders need a Seed syndicate that can sustain the company through eighteen to twenty-four months of African operating reality. Ask explicitly about reserves, follow-on into hard rounds, and which Series A leads the fund has brought into portfolio companies. African Series A capital is structurally scarce for healthcare specifically, so confirm the path to the next round is real. Reference checks with portfolio founders, particularly on speed of decisions and operating support, are worth the time. Used appropriately, Ingressive is one of the more credible early partners for African healthcare and AI founders building from the continent.